Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. – January 1st – 31st, 2026
Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
Buyout/LBO
- Laysan Bio, specialty bioconjugation and biomaterials reagents that serve biotechnology and life sciences markets, acquired by Gannet BioChem, via its financial sponsor Ampersand Capital Partners, through an LBO.
- Nivagen Pharmaceuticals, a pharmaceutical company that develops, manufactures, and markets pharmaceutical products across generics and specialty drugs, acquired by PAI Pharma, via its financial sponsors Apollo Global Management and Olympus Partners, through an LBO.
- Tampa Bay Medical Research, clinical research and trial services that advance medical knowledge and expand access to innovative treatments for a range of health conditions, acquired by Alcanza Clinical Research, via its financial sponsors Martis Capital Management, ICP Group, Alpha Leonis Partners and Impact Engine, through an LBO.
- Hartley Medical Center Pharmacy, a compounding pharmacy facility that serves healthcare professionals involved in pain management and spasticity care, acquired by Pentec Health, via its financial sponsors Revelar Capital and Golub Capital, through an LBO..
Early Stage VC
- Spearhead Bio, a native genome engineering platform that enhances the efficiency of crop genome engineering, raised $4 million of venture funding.
- AirNexis Therapeutics, novel therapeutic drugs that treat COPD patients, raised $200 million of Series A venture funding in a deal led by Frazier Healthcare Partners.
- Caldera Therapeutics, a clinical-stage biotechnology company that develops a bispecific antibody for the treatment of inflammatory bowel disease, raised $37.5 million of Series A1 venture funding in a deal led by Omega Funds.
Accelerator/Incubator
- Informuta, precision diagnostic tools that analyze whole genome sequencing data to inform clinical treatment decisions, joined The Idea Village as part of its VILLAGEx accelerator program.
Angel
- Immorta Bio, a scientific longevity platform that reverses aging and treats age-related diseases, raised $450,000 of angel funding.
- Mivax Therapeutics, a biotechnology company that provides treatments, raised $202,500 of angel funding.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharma #drug #drugdiscovery #drugdelivery
Diana Ruddy
Managing Director
Over 20 years of diverse experience in investment banking, consulting, and commercial lending. Developed transactions up to $350 million, sourcing debt and equity funding for domestic and international projects across a wide range of industries. Advised companies on expansion, mergers and acquisitions, financial structure, contract negotiation, and strategic planning. Industry experience includes healthcare, technology, energy, aviation, real estate, manufacturing, retail, agriculture, hospitality, financial services, and nonprofits. Bachelor of Science with highest honors in Finance from UMass Boston, and MBA with great distinction from Arizona State University W.P. Carey School of Business. FINRA Series 7, 66, 79 and 99 licenses.
- Email: druddy@castleplacement.com
- (C) (406) 868-3218
Diana Ruddy
Managing Director
Please contact me if you have any questions or would like to discuss your capital raise:
Email: druddy@castleplacement.com
(C) (406) 868-3218
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
